Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Item 9 Labs Corp. INLB OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
24/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Item 9 Labs Corp. (INLB) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $22M, +78%/yr average growth. Net income is $31M (loss), growing at -46.6%/yr. Net profit margin is -143.1% (negative). Gross margin is 33.6% (-14.6 pp trend).

Balance sheet: total debt is $28M against $62M equity (Debt-to-Equity (D/E) ratio 0.45, conservative). Current ratio is 0.09 (tight liquidity). Debt-to-assets is 25.1%. Total assets: $111M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

INLB SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — INLB

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
INLB: +78%/yr revenue is, -46.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet INLB: Debt-to-Equity (D/E) ratio 0.45 (conservative), Current ratio is 0.09 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
INLB: Gross margin is 33.6% (-14.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
INLB: Net profit margin is -143.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0001-0.0001
Volume20K
Avg Volume (30D)10.9K
Market Cap$70.18K
Beta (1Y)0.07
Share Statistics
EPS (TTM)-0.33
Shares Outstanding$95.69M
IPO Date2012-01-25
Employees97
CEOJeffrey I. Rassas
Financial Highlights & Ratios
Revenue (TTM)$21.76M
Gross Profit$7.31M
EBITDA$-22.83M
Net Income$-31.14M
Operating Income$-23.07M
Total Cash$85.64K
Total Debt$27.85M
Net Debt$27.76M
Total Assets$110.76M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS46564C2035

Price Chart

Track all markets on TradingView
INLB
Item 9 Labs Corp. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic

People Also View

GRUSF
GRUSF
Grown Rogue International Inc.
$0.32
+0.75%
 DBCCF
DBCCF
Decibel Cannabis Company Inc.
$0.09
-4.33%
 CANSF
CANSF
Willow Biosciences Inc.
$0.11
+0.00%
 CXXIF
CXXIF
C21 Investments Inc.
$0.31
+15.12%
 RAMMF
RAMMF
RAMM Pharma Corp.
$0.06
+0.00%
 CLSH
CLSH
CLS Holdings USA, Inc.
$0.04
+0.00%
 DLTNF
DLTNF
Delta 9 Cannabis Inc.
$0.01
-1.95%
 KAYS
KAYS
Kaya Holdings, Inc.
$0.03
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message